Parantu K. Shah

Ono Pharmaceutical (United States) — United States

Medicine · Health Sciences

26h-index7.8kcitations90works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(15), Protein Degradation and Inhibitors(11), Cancer Mechanisms and Therapy(10), Cancer Genomics and Diagnostics(9), Chromatin Remodeling and Cancer(9)

Publications89 total

MLH1 Mismatch Repair Deficiency Predicts Exceptional Response to Immune Checkpoint Inhibition in Clear-cell Renal Cell Carcinoma
European Urology·2025
Association of <i>IL7</i> germline variants with immune-related adverse events (irAEs) in cancer patients (pts) treated with immune checkpoint inhibitors (ICIs).
Journal of Clinical Oncology·2025
Abstract 1177: Tumor-associated macrophages and clinical outcomes to immunotherapy
Cancer Research·2025
MP28-05 MLH1 MISMATCH REPAIR PREDICTS EXCEPTIONAL RESPONDER PHENOTYPES IN CLEAR-CELL RENAL CELL CARCINOMA
The Journal of Urology·2025
<i>NECTIN4</i> RNA expression and clinical outcomes with first-line (1L) platinum-based chemotherapy (PBC) and avelumab 1L maintenance in locally advanced or metastatic urothelial carcinoma (la/mUC): Exploratory analyses from JAVELIN Bladder 100.
Journal of Clinical Oncology·2025
Supplementary Data 1 from Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma
2024Open Access
Data from Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma
2024Open Access
22 Association of a germline single nucleotide polymorphism (SNP) in the interleukin-7 (IL7) gene with immune-related adverse events (irAEs)
The Oncologist·2024· 1 citedOpen Access
Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma
Clinical Cancer Research·2024· 8 citedOpen Access
Avelumab first‐line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the <scp>JAVELIN</scp> Bladder 100 phase 3 trial
Cancer Medicine·2024· 2 citedOpen Access
supplementary Figures S1-S10 from Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
2023Open Access
Data from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
Data from Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
2023Open Access
Supplementary Figures 1 - 8 from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
Supplementary Figures 1 - 8 from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
supplementary material and method from Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
2023Open Access
Supplementary Methods, Figure Legends from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
Supplementary Methods, Figure Legends from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
Data from Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
2023Open Access
Data from The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Nikhil C. Munshi(13), Stéphane Minvielle(12), Hervé Avet‐Loiseau(11), Kenneth C. Anderson(7), Samirkumar B. Amin(7), Kevin P. White(6), Florence Magrangeas(6), Peer Bork(5), Sandra P. D’Angelo(5), Sara Georges(5), Nicolas Nègre(4), Giulio Draetta(4), Jannik N. Andersen(4), Paul Nghiem(4), Xujun Wang(4), Timothy P. Heffernan(3), Carlo Toniatti(3), Philip Jones(3), Andrew S. Brohl(3), Célèste Lebbé(3)